SPC Logo

Voltarol Active 4% cutaneous Spray

Last Updated on eMC 21-Jun-2012 View changes  | Novartis Consumer Health Contact details

Discontinued Items

The preparations being discontinued are:

  • Voltarol Active 4% spray (Novartis Consumer Health UK Ltd)

The pharmaceutical company has decided to discontinue the product and so it may not be available in the future.  This document has been left on the eMC for information purposes.

1. Name of the medicinal product

Voltarol® Active 4% cutaneous spray

2. Qualitative and quantitative composition

1g of Voltarol Active 4% cutaneous spray contains 40 mg of diclofenac sodium.

Each pump stroke delivers 8 mg of diclofenac sodium.

Excipients:

Propylene glycol 150 mg/g

Soy bean lecithin 100 mg/g

For a full list of excipients, see section 6.1.

3. Pharmaceutical form

Cutaneous spray, solution.

A golden-yellow, transparent solution (pH value: 6.5–7.6), which turns to a gel-like consistency after administration.

4. Clinical particulars
4.1 Therapeutic indications

For the local symptomatic relief of mild to moderate pain and inflammation following acute blunt trauma of small and medium-sized joints and periarticular structures.

4.2 Posology and method of administration

For cutaneous use only.

Adults and adolescents aged 14 years and over

Sufficient solution of Voltarol Active 4% cutaneous spray should be sprayed onto the skin of the affected site. Depending on the size to be treated, 4–5 pump strokes (0.8–1.0 g of spray containing 32–40 mg of diclofenac sodium) should be applied 3 times a day at regular intervals. The maximum single dose of 1.0 g of the product should not be exceeded. The maximum daily dose is 15 pump strokes (3.0 g of spray containing 120 mg of diclofenac sodium).

Voltarol Active 4% cutaneous spray should be massaged gently into the skin. After this the hands should be washed unless they are the site to be treated. After application some minutes for drying should be allowed before dressing or binding the treated area.

The treatment may be discontinued when the symptoms (pain and swelling) have subsided. Treatment should not be continued beyond 7 days without review. The patient is requested to consult the doctor if no improvement is seen after 3 days.

Children and adolescents

There are insufficient data on efficacy and safety available for children and adolescents below 14 years (see also contraindication section 4.3.

In adolescents aged 14 years and over, if this product is required for more than 7 days for pain relief or if the symptoms worsen the patient/parents of the adolescent is/are advised to consult a doctor.

Elderly

The posology is the same as for adults.

Patients with hepatic or renal insufficiency

For the use of Voltarol Active 4% cutaneous spray in patients with hepatic or renal insufficiency see section 4.4.

4.3 Contraindications

• Hypersensitivity to diclofenac, peanut, soya or to any of the excipients. Hypersensitivity to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs)

• Patients with or without asthma in whom attacks of asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid or other NSAIDs.

• During the third trimester of pregnancy.

• Application to the breast area of breast-feeding mothers

• Use in children and adolescents less than 14 years is contraindicated.

4.4 Special warnings and precautions for use

The possibility of systemic adverse events from application of Voltarol Active 4% cutaneous spray cannot be excluded if the preparation is used on large areas of skin and over a prolonged period (see the product information on systemic forms of diclofenac).

Voltarol Active 4% cutaneous spray should be applied only to intact non-diseased skin, and not to skin wounds or open injuries. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested.

Voltarol Active 4% cutaneous spray can be used with non-occlusive bandages but should not be used with an airtight occlusive dressing.

Patients should be warned against excessive exposure to sunlight in order to reduce the incidence of photosensitivity.

Discontinue the treatment if a skin rash develops after applying the product.

The concomitant use of Voltarol Active 4% cutaneous spray with oral NSAIDs should be cautioned as the incidence of systemic undesirable effects may increase (see section 4.5).

Where Voltarol Active 4% cutaneous spray is applied to a relatively large area of skin (i.e. more than 600 square centimetres of the body surface) and over a prolonged period (i.e. more than 4 weeks), the possibility of systemic undesirable effects from application of Voltarol Active 4% cutaneous spray cannot be excluded (for example, there is the potential for hypersensitivity, asthmatic and renal adverse reactions). Bronchospasm may be precipitated in patients suffering from or with previous history of bronchial asthma or allergenic disease.

Voltarol Active 4% cutaneous spray should only be used with caution in patients with a history of peptic ulcer, hepatic or renal insufficiency, or bleeding diathesis, or inflammatory bowel disease, as isolated cases with topical diclofenac have been reported.

Information concerning excipients

Voltarol Active 4% cutaneous spray contains:

propylene glycol which may cause skin irritation in some people.

peppermint oil which may cause allergic reactions.

4.5 Interaction with other medicinal products and other forms of interaction

Since systemic absorption of diclofenac from a topical application of Voltarol Active 4% cutaneous spray is very low such interactions are very unlikely.

Concurrent acetylsalicylic acid or other NSAIDs may result in an increased incidence of adverse reactions (see section 4.4).

4.6 Pregnancy and lactation

PregnancyThe systemic concentration of Voltarol Active 4% cutaneous spray is lower after topical administration, compared to oral formulations. With reference to experience from treatment with NSAIDs with systemic uptake, the following is recommended:

Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.

During the first and second trimester of pregnancy, Voltarol Active 4% cutaneous spray should not be given unless clearly necessary. If Voltarol Active 4% cutaneous spray is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.

During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:

• cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);

• renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;

The mother and the neonate, at the end of pregnancy, to:

• possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.

• inhibition of uterine contractions resulting in delayed or prolonged labour.

• Consequently, diclofenac is contraindicated during the third trimester of pregnancy.

Lactaction

Like other NSAIDs, diclofenac passes into breast milk in small amounts. However, at therapeutic doses of Voltarol Active 4% cutaneous spray no effects on the suckling child are anticipated. Because of a lack of controlled studies in lactating women, the product should only be used during lactation under advice from a healthcare professional. Under this circumstance, Voltarol Active 4% cutaneous spray should not be applied on the breasts of nursing mothers, nor to elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).

4.7 Effects on ability to drive and use machines

Cutaneous application of Voltarol Active 4% cutaneous spray has no influence on the ability to drive and use machines.

4.8 Undesirable effects

Skin disorders are commonly reported.

Adverse reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), or not known (can not to be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 1

Immune system disorder

 

Very rare

Hypersensitivity (including urticaria), angioneurotic oedema

Infections and infestations

 

Very rare

Rash pustular

Respiratory, thoracic and mediastinal disorders

 

Very rare

Asthma

Skin and subcutaneous tissue disorders

 

Common

Rash, eczema, erythema, dermatitis (including dermatitis contact), pruritus*

Rare

Dermatitis bullous

Very rare

Photosensitivity reaction

Not known

Application site reaction, dry skin, burning sensation

* Pruritus has been reported at a frequency of 0.9% in a clinical trial, 236 patients with ankle distortions were treated with 4–5 pump strokes of Voltarol Active 4% cutaneous spray t.i.d. (120 patients) or placebo (116 patients) for 14 days.

Undesirable effects may be reduced by using the minimum effective dose for the shortest possible duration. The total single dose of product should not exceed 1.0 g (equivalent to 5 pump strokes) of spray.

Nevertheless during long term treatment (> three weeks) and/or when treating large areas (i.e. more than 600 square centimetres of the body surface) there is a possibility of systemic adverse reactions. Reactions like abdominal pain, dyspepsia, gastric and renal disorders may occur.

4.9 Overdose

The low systemic absorption of topical diclofenac renders overdose very unlikely.

However undesirable effects similar to those observed following an overdose of diclofenac tablets can be expected if Voltarol Active 4% cutaneous spray is inadvertently ingested (i.e. a 15 ml spray bottle containing 500 mg of diclofenac sodium).

In the event of accidental ingestion resulting in significant systemic adverse effects, general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory medicines should be used. Gastric decontamination and the use of activated charcoal should be considered, especially within a short time of ingestion.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antiinflammatory preparations, non-steroids for topical use.

ATC code: M02AA 15

Sodium diclofenac is a non-steroidal anti-inflammatory drug (NSAID) which has also analgesic properties. The inhibition of prostaglandin synthesis is considered to be an essential part of its mode of action.

5.2 Pharmacokinetic properties

After cutaneous application of 1.5 g Voltarol Active 4% cutaneous spray a rapid onset of diclofenac absorption can be observed leading to measurable plasma levels of about 1 ng/ml as early as 30 minutes and to maximum levels of about 3 ng/ml at about 24 hours after application.

The achieved systemic concentrations of diclofenac are about 50 times lower than those achieved following oral administration of equivalent amounts of diclofenac. Systemic plasma levels are not supposed to contribute to the efficacy of Voltarol Active 4% cutaneous spray.

Diclofenac is extensively bound to plasma proteins (about 99 %).

5.3 Preclinical safety data

In rabbit skin, Voltarol Active 4% cutaneous spray is classified as non-irritant.

Non-clinical data based on conventional studies of safety pharmacology, genotoxicity and carcinogenic potential of diclofenac reveal no special hazard for humans beyond those already outlined in other sections of the SPC. In animal studies, chronic toxicity of diclofenac following systemic administration mainly took the form of gastrointestinal lesions and ulcers. In a 2-year toxicity study, rats treated with diclofenac showed a dose-dependent increase in thrombotic occlusion of the cardiac vessels.

In rats and rabbits oral doses of diclofenac were not teratogenic but caused embryotoxicity at maternally toxic doses.

Diclofenac did not affect fertility in rats but inhibited ovulation in rabbits and reduced implantation in rats.

In rats, diclofenac resulted in dose-dependent constriction of the fetal ductus arteriosus, dystocia and delayed parturition (see section 4.3). Doses below the materno-toxic threshold had no influence on the postnatal development of the progeny.

6. Pharmaceutical particulars
6.1 List of excipients

Isopropyl alcohol

Soybean lecithin

Ethanol

Disodium phosphate dodecahydrate

Sodium dihydrogen phosphate dihydrate

Disodium edetate

Propylene glycol

Peppermint oil (contains menthol and cineole)

Ascorbyl palmitate

Hydrochloric acid 10% (w/w) for pH adjustment

Sodium hydroxide 10% (w/w) for pH adjustment

Purified water.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

After first opening: 6 months

6.4 Special precautions for storage

Store in the original package.

6.5 Nature and contents of container

Glass bottle (Type III Ph.Eur.) with metering pump and protection cap.

Pack sizes of 12.5 g solution (15 ml bottle) and 25 g solution (30 ml bottle).

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements.

7. Marketing authorisation holder

Novartis Consumer Health UK Limited

Wimblehurst Road, Horsham

West Sussex – RH12 5AB

United Kingdom

8. Marketing authorisation number(s)

PL 00030/0445

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 29/08/2008

10. Date of revision of the text

18/05/2012

11 Dosimetry (if applicable)

Not applicable

12 Instructions for preparation of radiopharmaceuticals (if applicable)

Not applicable

Legal category

P

Company contact details

Novartis Consumer Health

Company image
Address

Novartis Consumer Health UK Ltd, Park View, Riverside Way, Watchmoor Park, Camberley, Surrey, GU15 3YL, UK

Fax

+44 (0)1276 687284

Medical Information e-mail
Medical Information Fax

+44 (0)1276 687288

Telephone

+44 (0)1276 687300

Medical Information Direct Line

+44 (0)1276 687202

Customer Care direct line

+44 (0)1276 687290

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

diclofenac sodium

Legal categories

P - Pharmacy

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue